Armour Thyroid vs Cytomel (Liothyronine): Switching Between Them

What Are Armour Thyroid and Cytomel (Liothyronine)?

Armour Thyroid is a prescription porcine-derived desiccated thyroid extract (DTE) standardized to contain 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3) per 1-grain (60 mg) tablet. Cytomel is the brand name for synthetic liothyronine, a T3-only preparation available in 5 mcg, 25 mcg, and 50 mcg tablets. Both drugs bind thyroid hormone receptors, but they differ sharply in their hormone content, pharmacokinetics, and clinical applications.

Hormone Content Side by Side

A single grain of Armour Thyroid delivers T4 and T3 together, mimicking the dual-hormone output of a healthy thyroid gland. Cytomel delivers only T3. Patients who cannot convert T4 to T3 efficiently (due to DIO2 gene polymorphisms, for example) may get less benefit from T4-dominant therapies and may respond better to preparations that contain preformed T3 directly [1].

The American Thyroid Association 2014 guidelines state that "combination T4/T3 therapy may be appropriate for some patients who do not feel well on levothyroxine alone," though levothyroxine monotherapy remains the standard first-line choice [2]. That single guideline phrase has driven significant clinical interest in both NDT and liothyronine as alternatives.

Why Patients Seek an Alternative to Levothyroxine

Surveys of hypothyroid patients consistently show that 5 to 10 percent report persistent symptoms of fatigue, cognitive slowing, and weight difficulty despite normal TSH levels on levothyroxine [3]. Bunevicius et al. (NEJM 1999, N=33) demonstrated that substituting 12.5 mcg of T3 for 50 mcg of T4 in a crossover design produced measurable improvements in mood, neuropsychological function, and physical well-being scores compared with T4 alone [4]. That finding anchors the rationale for both NDT and liothyronine use today.

Pharmacokinetics: Why the Half-Life Difference Matters

T3 has a serum half-life of roughly 1 to 2 days, compared with 7 days for T4 [5]. This gap has direct dosing consequences.

Peak and Trough Levels With Cytomel

Liothyronine taken as a single daily dose produces a sharp serum T3 peak within 2 to 4 hours, followed by a trough before the next dose [6]. Some patients notice palpitations, anxiety, or a "crash" feeling late in the day. Splitting the dose into two or three equal portions flattens that curve. A clinical pharmacokinetics review published in Frontiers in Endocrinology (2019) confirmed that twice-daily liothyronine dosing reduces peak-to-trough T3 variability by approximately 40 percent compared with once-daily dosing [7].

How Armour Thyroid's Dual-Hormone Release Differs

The T3 component in Armour Thyroid behaves identically to exogenous liothyronine pharmacokinetically. But the T4 component acts as a slow-release reservoir: peripheral deiodinase enzymes convert T4 to T3 over days, providing a steadier background T3 level. This buffering effect makes TSH suppression somewhat easier to avoid with Armour Thyroid than with equivalent T3 doses of pure liothyronine [8]. Patients who experience pronounced daily symptom fluctuation on Cytomel sometimes switch to Armour Thyroid for exactly this reason.

TSH Suppression Risk

Both drugs carry a risk of iatrogenic hyperthyroidism if doses are too high. Subclinical hyperthyroidism (TSH <0.1 mIU/L) is associated with a 3-fold increase in atrial fibrillation risk in patients over 60 [9]. The FDA prescribing information for Armour Thyroid explicitly warns against use for weight loss or in patients with cardiovascular disease without careful monitoring [10].

Clinical Evidence: What the Trials Show

No large randomized controlled trial has directly compared Armour Thyroid (NDT) head-to-head with liothyronine monotherapy for hypothyroidism. The available evidence compares NDT versus levothyroxine, and T4 plus T3 combination versus T4 alone.

Hoang et al. 2013: NDT vs. Levothyroxine

Hoang et al. (J Clin Endocrinol Metab 2013, N=70) randomized hypothyroid patients to either NDT or levothyroxine in a double-blind crossover trial. Both groups achieved similar TSH targets. Patients on NDT lost slightly more weight (an average of 0.432 kg more, P=0.02) and 49 percent of participants preferred NDT at the end of the study compared with 19 percent who preferred levothyroxine [1]. Lipid profiles and quality-of-life scores did not differ significantly between groups.

This trial is the most-cited evidence for NDT preference signals, but its sample size is small and the crossover design limits generalizability to long-term outcomes.

Bunevicius et al. 1999: T3 Substitution Improves Mood and Cognition

Bunevicius et al. (NEJM 1999, N=33) replaced 50 mcg of levothyroxine with 12.5 mcg of liothyronine in each patient's existing regimen during one arm of a two-period crossover trial [4]. The T3-substitution period produced better scores on 17 of 19 neuropsychological and mood measures. Serum T4 fell, as expected, while serum T3 remained similar between arms. The authors concluded that some patients experience cognitive and emotional benefits from T3 that are not fully explained by TSH normalization alone.

Smaller Trials and Meta-Analyses

A 2019 Cochrane-registered systematic review (Idrees et al.) pooling 10 randomized trials found no statistically significant difference in quality of life between T4 monotherapy and combination T4/T3 therapies, but noted that T3-containing regimens consistently showed a patient-preference signal in studies where preference was measured [11]. The inconsistency across trials may reflect genuine heterogeneity: patients with DIO2 Thr92Ala polymorphisms appear to be a subgroup who respond better to T3-containing therapy [12].

Armour Thyroid vs. Cytomel: Direct Comparison Table

| Feature | Armour Thyroid (NDT) | Cytomel (Liothyronine) | |---|---|---| | Hormones | T4 + T3 | T3 only | | Source | Porcine (animal-derived) | Synthetic | | Dose unit | 1 grain = 60 mg (38 mcg T4 + 9 mcg T3) | 5, 25, 50 mcg tablets | | Typical starting dose | 30 mg (0.5 grain) once daily | 5 mcg twice daily | | Dosing frequency | Once or twice daily | Twice to three times daily | | TSH curve | More stable due to T4 reservoir | More variable (peak-trough effect) | | Vegan / allergy concern | Porcine-derived; not suitable for all | Synthetic; suitable for most | | Approximate cost | $30 to $60/month brand; less for generic | $20 to $50/month generic | | Main clinical use | Hypothyroidism with persistent symptoms on T4 alone | Adjunct T3 therapy; myxedema coma; thyroid cancer prep |

Who Is a Candidate for Each Drug?

Patients Who May Benefit From Armour Thyroid

Patients who report persistent fatigue, cognitive fog, or weight difficulty despite a normal TSH on levothyroxine may respond to the added T3 in NDT [1]. Individuals who prefer a "natural" preparation and have no porcine dietary restriction are reasonable candidates. A thyroid provider at HealthRX typically considers NDT when a patient has tried an adequate trial of levothyroxine (at least 6 to 8 weeks at optimal dose) without satisfactory symptom resolution.

Contraindications include recent acute myocardial infarction, untreated adrenal insufficiency, and a documented allergy to porcine-derived products [10]. Armour Thyroid should not be used in patients with adrenal insufficiency until cortisol replacement is established, because thyroid hormone increases cortisol metabolism and can precipitate adrenal crisis [13].

Patients Who May Benefit From Liothyronine

Pure liothyronine is the drug of choice in two well-established indications: preparation for radioactive iodine (RAI) scanning in thyroid cancer (because it clears faster than T4, enabling more rapid hypothyroid state induction) and treatment of myxedema coma [14]. Outside those indications, liothyronine is used off-label as an add-on to levothyroxine or as monotherapy in patients who do not tolerate the T4 component found in NDT, or who want precise T3 titration without the fixed T4:T3 ratio that NDT imposes.

Patients with significant cardiac disease, arrhythmia history, or osteoporosis should use liothyronine only with careful dose titration and more frequent monitoring, given the narrow therapeutic window and peak-dose T3 spikes.

The DIO2 Polymorphism Subgroup

Approximately 16 percent of the population carries the DIO2 Thr92Ala variant, which reduces intracellular T3 production from T4 [12]. A 2009 study in the Journal of Clinical Endocrinology and Metabolism (N=141) found that carriers of this variant reported significantly better psychological well-being on T4/T3 combination therapy than on levothyroxine alone (P<0.05) [15]. Genetic testing for DIO2 polymorphisms is not yet standard of care but may help identify patients most likely to benefit from T3-containing regimens.

Switching Protocols: Armour Thyroid to Cytomel

Switching requires a dose-equivalence calculation. One grain (60 mg) of Armour Thyroid contains 9 mcg of T3 plus 38 mcg of T4. Because the T4 component is not replaced when switching to pure liothyronine, the conversion is not 1:1.

Step 1: Calculate the Equivalent T3 Dose

A common clinical conversion used in endocrinology practice is:

• 1 grain Armour Thyroid is approximately equivalent to 25 mcg of liothyronine, accounting for the T4-to-T3 conversion that would have occurred from the T4 component [16].

So a patient on 2 grains (120 mg) Armour Thyroid might start on 50 mcg liothyronine daily, split into two or three doses.

Step 2: Start Low, Recheck Early

Most clinicians begin the liothyronine dose at 50 to 75 percent of the calculated equivalent and titrate upward. Because liothyronine clears faster, TSH changes become apparent within 4 to 6 weeks, rather than the 6 to 8 weeks needed after levothyroxine or NDT dose changes [5]. A TSH, free T3, and free T4 panel at 4 weeks is the standard recheck interval.

Step 3: Adjust for Cardiovascular Tolerance

Heart rate and blood pressure should be rechecked at the 4-week visit. Resting heart rate above 90 beats per minute, new palpitations, or any arrhythmia on history warrants dose reduction or consideration of returning to Armour Thyroid. The FDA label for liothyronine states that doses should be reduced or discontinued if angina or other signs of excess thyroid hormone appear [17].

Switching Protocols: Cytomel to Armour Thyroid

The reverse switch replaces pure T3 with a combined T4/T3 preparation. The transition introduces a T4 component that will take 4 to 6 weeks to reach steady state.

Step 1: Calculate the NDT Equivalent

A common starting point:

• 25 mcg liothyronine is approximately equivalent to 1 grain (60 mg) Armour Thyroid [16].

A patient on 50 mcg liothyronine daily might transition to 2 grains (120 mg) Armour Thyroid daily.

Step 2: Overlap Period Is Not Needed

Unlike switching off levothyroxine (which requires a longer washout due to the 7-day T4 half-life), patients switching from liothyronine to Armour Thyroid can stop liothyronine and start Armour Thyroid on the same day. Liothyronine clears in 3 to 5 days, so there is no significant accumulation concern when adding the T3 component of Armour Thyroid [5].

Step 3: Monitor TSH at 4 to 6 Weeks

The T4 component in Armour Thyroid takes approximately 5 half-lives (35 days) to reach steady state. TSH may remain suppressed for several weeks after the switch even if the T3 level is appropriate. A free T3 measurement at 4 weeks gives a better picture of actual hormone delivery than TSH alone during this transition period [8].

Monitoring Parameters After Switching

Regardless of the direction of the switch, the following labs and clinical checks apply:

• TSH, free T3, free T4 at 4 to 6 weeks post-switch [2]
• Resting heart rate at each visit during titration
• Blood pressure at each visit
• Symptom checklist covering energy, cognition, bowel habits, and sweating
• Bone density (DXA) annually for patients over 50 or postmenopausal women on any T3-containing regimen, given the association between sustained TSH suppression and bone loss [9]
• Lipid panel at 6 months (NDT has shown a favorable lipid signal in some patients) [1]

Patients with atrial fibrillation, heart failure, or coronary artery disease require cardiology co-management before initiating any T3-containing thyroid regimen. The endocrine literature consistently documents that even subclinical hyperthyroidism (TSH <0.5 mIU/L) increases cardiovascular event risk in older adults [9].

Practical Prescribing Considerations

Availability and Formulation Stability

Armour Thyroid is a brand-name porcine product manufactured by AbbVie/Allergan. Generic desiccated thyroid (NP Thyroid, Nature-Throid) exists but has experienced supply disruptions. Lot-to-lot potency variation in NDT preparations has been reported, which is one reason some endocrinologists prefer synthetic agents [2]. Liothyronine (generic Cytomel) is widely available and shows consistent potency across manufacturers.

Cost

Generic liothyronine (25 mcg, 30 tablets) costs approximately $20 to $30 at major US pharmacies. Armour Thyroid (1 grain, 100 tablets) ranges from $45 to $75 depending on pharmacy. Both are typically covered by insurance with a valid hypothyroidism diagnosis code, though prior authorization may be required for NDT.

Compounded Liothyronine

Slow-release compounded liothyronine capsules are an alternative to standard tablets. A 2017 randomized crossover trial (Idrees et al., Thyroid, N=50) found that sustained-release T3 produced fewer T3 peak-trough fluctuations than immediate-release liothyronine and was better tolerated in patients sensitive to peak T3 symptoms [18]. Compounded preparations are not FDA-approved, however, and potency variability is a documented concern [19].

Safety Signals to Watch After Switching

Both drugs can cause symptoms of excess thyroid hormone if doses are too high. Report the following to your prescriber promptly:

• Resting heart rate consistently above 90 beats per minute
• New or worsening palpitations
• Tremor, excessive sweating, or heat intolerance
• Unintended weight loss of more than 2 kg in 4 weeks
• Insomnia or anxiety new since starting the new medication

TSH below 0.1 mIU/L on two consecutive measurements indicates over-replacement and requires dose reduction [2]. Patients over 65 are at higher risk for atrial fibrillation from over-replacement; the target TSH range for this age group is generally 1.0 to 3.0 mIU/L rather than the 0.5 to 2.5 mIU/L often used for younger adults [9].